Francisca Mutapi, Amadou Garba, Mark Woolhouse, Paul Kazyoba
{"title":"Paediatric schistosomiasis: last mile preparations for deploying paediatric praziquantel.","authors":"Francisca Mutapi, Amadou Garba, Mark Woolhouse, Paul Kazyoba","doi":"10.1016/j.pt.2024.06.011","DOIUrl":null,"url":null,"abstract":"<p><p>Schistosomiasis is the second most important parasitic disease of public health importance in Africa, affecting over 50 million children aged <5 years old. Schistosomiasis control has focused on treating school-aged children (>6 years) and adults through mass drug administration (MDA). Following the recent development of a paediatric praziquantel (PZQ) formulation for children aged <5 years, there are now concerted efforts to determine optimal and effective ways to integrate treatment of these children into national schistosomiasis control programmes. In this opinion article we outline the pathway for successful drug access, delivery, and mainstreaming of the new formulation in endemic country health systems. Effective and sustained paediatric schistosomiasis treatment is an important target of the 2030 World Health Organization (WHO) neglected tropical diseases (NTDs) roadmap.</p>","PeriodicalId":23327,"journal":{"name":"Trends in parasitology","volume":null,"pages":null},"PeriodicalIF":7.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in parasitology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pt.2024.06.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Schistosomiasis is the second most important parasitic disease of public health importance in Africa, affecting over 50 million children aged <5 years old. Schistosomiasis control has focused on treating school-aged children (>6 years) and adults through mass drug administration (MDA). Following the recent development of a paediatric praziquantel (PZQ) formulation for children aged <5 years, there are now concerted efforts to determine optimal and effective ways to integrate treatment of these children into national schistosomiasis control programmes. In this opinion article we outline the pathway for successful drug access, delivery, and mainstreaming of the new formulation in endemic country health systems. Effective and sustained paediatric schistosomiasis treatment is an important target of the 2030 World Health Organization (WHO) neglected tropical diseases (NTDs) roadmap.
期刊介绍：
Since its inception as Parasitology Today in 1985, Trends in Parasitology has evolved into a highly esteemed review journal of global significance, reflecting the importance of medical and veterinary parasites worldwide. The journal serves as a hub for communication among researchers across all disciplines of parasitology, encompassing endoparasites, ectoparasites, transmission vectors, and susceptible hosts.
Each monthly issue of Trends in Parasitology offers authoritative, cutting-edge, and yet accessible review articles, providing a balanced and comprehensive overview, along with opinion pieces offering personal and novel perspectives. Additionally, the journal publishes a variety of short articles designed to inform and stimulate thoughts in a lively and widely-accessible manner. These include Science & Society (discussing the interface between parasitology and the general public), Spotlight (highlighting recently published research articles), Forum (presenting single-point hypotheses), Parasite/Vector of the Month (featuring a modular display of the selected species), Letter (providing responses to recent articles in Trends in Parasitology), and Trendstalk (conducting interviews). Please note that the journal exclusively publishes literature reviews based on published data, with systematic reviews, meta-analysis, and unpublished primary research falling outside our scope.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
